AR‐42 treatment reduced IL‐6RA and GP130 mRNA (Fig 7G) similar to reports of AR‐42 activity in multiple myeloma cells (Zhang et al, 2011) and the activity of pan‐HDACis in naïve CD4+ T cells (Glauben et al, 2014). This evidence concerns the gene IL6R and plasma cell myeloma.